Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Trial details
- Registry ID
- NCT06881784
- Phase
- Phase 3
The FDA approved daraxonrasib on 26 Aug 2026.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 | RVMD | Phase 3 | Recruiting | 2027-12-01Estimated |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07491445 | RVMD | Phase 3 | Recruiting | 2028-04Estimated |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)NCT07252232 | RVMD | Phase 3 | Recruiting | 2029-05-10Estimated |
| Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaNCT07805954 | RVMD | Phase 3 | Recruiting | 2029-03Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-08-26Day | daraxonrasib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA220910", "applicant_as_listed_by_fda": "REVOLUTION MEDICINES", "brand_names": ["RASONQUE"], "active_ingredients": ["DARAXONRASIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20260826", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |